Autopsy report · NCT01359007
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
Cause of deathSlow enrollment, also staffing, sites or logistics
“The principal investigator terminated the study due to inactivity and low enrollment”
Life of this trial
- Ran for about 2 years 5 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 4 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Conditions
- Adenocarcinoma of Pancreas
- Interventions
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Participants
- 5
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
“The study was terminated due to low enrollment” - Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
“This study was terminated due to low participant enrollment.” - BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
“Study was terminated due to low enrollment.” - Use of Teriparatide to Accelerate Fracture Healing
“The study was terminated due to poor enrollment.” - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
“The study is terminated due to lower enrollment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.